• Je něco špatně v tomto záznamu ?

RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD

V. Koblizek, B. Milenkovic, M. Svoboda, J. Kocianova, S. Holub, V. Zindr, M. Ilic, J. Jankovic, V. Cupurdija, J. Jarkovsky, B. Popov, A. Valipour

. 2023 ; 18 (-) : 2661-2672. [pub] 20231117

Jazyk angličtina Země Nový Zéland

Typ dokumentu multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000652

PURPOSE: The Phenotypes of COPD in Central and Eastern Europe (POPE) study assessed the prevalence and clinical characteristics of four clinical COPD phenotypes, but not mortality. This retrospective analysis of the POPE study (RETRO-POPE) investigated the relationship between all-cause mortality and patient characteristics using two grouping methods: clinical phenotyping (as in POPE) and Burgel clustering, to better identify high-risk patients. PATIENTS AND METHODS: The two largest POPE study patient cohorts (Czech Republic and Serbia) were categorized into one of four clinical phenotypes (acute exacerbators [with/without chronic bronchitis], non-exacerbators, asthma-COPD overlap), and one of five Burgel clusters based on comorbidities, lung function, age, body mass index (BMI) and dyspnea (very severe comorbid, very severe respiratory, moderate-to-severe respiratory, moderate-to-severe comorbid/obese, and mild respiratory). Patients were followed-up for approximately 7 years for survival status. RESULTS: Overall, 801 of 1,003 screened patients had sufficient data for analysis. Of these, 440 patients (54.9%) were alive and 361 (45.1%) had died at the end of follow-up. Analysis of survival by clinical phenotype showed no significant differences between the phenotypes (P=0.211). However, Burgel clustering demonstrated significant differences in survival between clusters (P<0.001), with patients in the "very severe comorbid" and "very severe respiratory" clusters most likely to die. Overall survival was not significantly different between Serbia and the Czech Republic after adjustment for age, BMI, comorbidities and forced expiratory volume in 1 second (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65-0.99; P=0.036 [unadjusted]; HR 0.88, 95% CI 0.7-1.1; P=0.257 [adjusted]). The most common causes of death were respiratory-related (36.8%), followed by cardiovascular (25.2%) then neoplasm (15.2%). CONCLUSION: Patient clusters based on comorbidities, lung function, age, BMI and dyspnea were more likely to show differences in COPD mortality risk than phenotypes defined by exacerbation history and presence/absence of chronic bronchitis and/or asthmatic features.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000652
003      
CZ-PrNML
005      
20240213093313.0
007      
ta
008      
240109e20231117nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/COPD.S426919 $2 doi
035    __
$a (PubMed)38022829
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Koblizek, Vladimir $u Department of Pneumology, University Hospital, Hradec Kralove, Czech Republic $u Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000224462790 $7 xx0076215
245    10
$a RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD / $c V. Koblizek, B. Milenkovic, M. Svoboda, J. Kocianova, S. Holub, V. Zindr, M. Ilic, J. Jankovic, V. Cupurdija, J. Jarkovsky, B. Popov, A. Valipour
520    9_
$a PURPOSE: The Phenotypes of COPD in Central and Eastern Europe (POPE) study assessed the prevalence and clinical characteristics of four clinical COPD phenotypes, but not mortality. This retrospective analysis of the POPE study (RETRO-POPE) investigated the relationship between all-cause mortality and patient characteristics using two grouping methods: clinical phenotyping (as in POPE) and Burgel clustering, to better identify high-risk patients. PATIENTS AND METHODS: The two largest POPE study patient cohorts (Czech Republic and Serbia) were categorized into one of four clinical phenotypes (acute exacerbators [with/without chronic bronchitis], non-exacerbators, asthma-COPD overlap), and one of five Burgel clusters based on comorbidities, lung function, age, body mass index (BMI) and dyspnea (very severe comorbid, very severe respiratory, moderate-to-severe respiratory, moderate-to-severe comorbid/obese, and mild respiratory). Patients were followed-up for approximately 7 years for survival status. RESULTS: Overall, 801 of 1,003 screened patients had sufficient data for analysis. Of these, 440 patients (54.9%) were alive and 361 (45.1%) had died at the end of follow-up. Analysis of survival by clinical phenotype showed no significant differences between the phenotypes (P=0.211). However, Burgel clustering demonstrated significant differences in survival between clusters (P<0.001), with patients in the "very severe comorbid" and "very severe respiratory" clusters most likely to die. Overall survival was not significantly different between Serbia and the Czech Republic after adjustment for age, BMI, comorbidities and forced expiratory volume in 1 second (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65-0.99; P=0.036 [unadjusted]; HR 0.88, 95% CI 0.7-1.1; P=0.257 [adjusted]). The most common causes of death were respiratory-related (36.8%), followed by cardiovascular (25.2%) then neoplasm (15.2%). CONCLUSION: Patient clusters based on comorbidities, lung function, age, BMI and dyspnea were more likely to show differences in COPD mortality risk than phenotypes defined by exacerbation history and presence/absence of chronic bronchitis and/or asthmatic features.
650    _2
$a lidé $7 D006801
650    12
$a chronická bronchitida $7 D029481
650    12
$a chronická obstrukční plicní nemoc $x epidemiologie $7 D029424
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a usilovný výdechový objem $7 D005541
650    _2
$a dyspnoe $x epidemiologie $7 D004417
650    _2
$a fenotyp $7 D010641
650    _2
$a progrese nemoci $7 D018450
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Milenkovic, Branislava $u Clinic for Pulmonary Diseases, Clinical Center of Serbia, Belgrade, Serbia $u Faculty of Medicine, University of Belgrade, Belgrade, Serbia $1 https://orcid.org/0000000207676869
700    1_
$a Svoboda, Michal $u Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kocianova, Jana $u Outpatient Department of Pneumology Alveolus, APRO MED, Ostrava, Czech Republic $1 https://orcid.org/0000000242709726
700    1_
$a Holub, Stanislav $u Outpatient Chest Clinic, Plicni Stredisko Teplice Ltd., Teplice, Czech Republic
700    1_
$a Zindr, Vladimir $u Outpatient Chest Clinic, PNEUMO KV Ltd., Karlovy Vary, Czech Republic
700    1_
$a Ilic, Miroslav $u Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia $u Clinic for Tuberculosis and Interstitial Lung Diseases, PolyClinic Department, Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia
700    1_
$a Jankovic, Jelena $u Clinic for Pulmonary Diseases, Clinical Center of Serbia, Belgrade, Serbia $u Faculty of Medicine, University of Belgrade, Belgrade, Serbia
700    1_
$a Cupurdija, Vojislav $u Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia $u Clinic for Pulmonology, University Clinical Center Kragujevac, Kragujevac, Serbia $1 https://orcid.org/0000000192310177
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Popov, Boris $u Medicine Department, Boehringer Ingelheim Serbia d.o.o. Beograd, Belgrade, Serbia
700    1_
$a Valipour, Arschang $u Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna Health Care Group, Vienna, Austria
773    0_
$w MED00165283 $t International journal of COPD $x 1178-2005 $g Roč. 18 (20231117), s. 2661-2672
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38022829 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093310 $b ABA008
999    __
$a ok $b bmc $g 2049349 $s 1210346
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c - $d 2661-2672 $e 20231117 $i 1178-2005 $m International journal of COPD $n Int. j. chronic obstr. pulm. dis. $x MED00165283
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace